Decision Diagnostics Corp.: DECN Comments on Recent Legal Filings by Federal Agencies
LOS ANGELES, CA / ACCESSWIRE / December 18, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., as well as the designer and manufacturer of the GenViro! Covid-19 Swift Kit testing kits, hereby confirms two recent legal filings by separate agencies of the Federal government regarding DECN and its CEO Keith Berman concerning its GenViro! Covid-19 testing products.
Keith Berman, the CEO of DECN, was charged yesterday in Los Angeles by the United States Department of Justice with one count of securities fraud and one count of making a false statement to government officials. It is alleged that Mr. Berman made false and misleading statements in connection with DECN s effort to develop, test and obtain regula
DECN Comments on Recent Legal Filings by Federal Agencies
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
DECN EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Decision Diagnostics Corp – DECN
businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
SEC Charges Biotech Company and CEO with Fraud Concerning COVID-19 Blood Testing Device
Washington, D.C. (Newsfile Corp. - December 18, 2020) - The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics securities on April 23, 2020.
The SEC s complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading stat
SEC Lawsuit Alleges Biotech Firm, CEO Misled Investors About COVID-19 Tests
The U.S. Securities and Exchange Commission sued Decision Diagnostics Corp. and its chief executive for allegedly misleading investors by promising the biotechnology company could test for COVID-19 with a finger-prick of blood and provide accurate results in less than one minute.
In a complaint filed on Thursday in Manhattan federal court, the SEC said Chief Executive Keith Berman made materially false statements between March and June about what he claimed was his company’s blood testing kit, and its efforts to obtain Food and Drug Administration approval for its emergency use.